Premium
When a randomized controlled trial is unlikely: Propensity score analysis of blinatumomab in adults with relapsed/refractory Philadelphia chromosome–positive B‐cell acute lymphoblastic leukemia
Author(s) -
Cassaday Ryan D.
Publication year - 2020
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.32565
Subject(s) - blinatumomab , medicine , propensity score matching , lymphoblastic leukemia , philadelphia chromosome , oncology , randomized controlled trial , refractory (planetary science) , cancer , leukemia , chromosomal translocation , genetics , gene , biology , astrobiology
A randomized controlled trial of blinatumomab for the treatment of patients with Philadelphia chromosome–positive B‐cell acute lymphoblastic leukemia is unlikely. In this issue of Cancer , Rambaldi et al perform a propensity score analysis to provide a comparison with historical standards of care.